Portolan Capital Management, LLC Castle Biosciences Inc Transaction History
Portolan Capital Management, LLC
- $1.38 Billion
- Q2 2025
A detailed history of Portolan Capital Management, LLC transactions in Castle Biosciences Inc stock. As of the latest transaction made, Portolan Capital Management, LLC holds 1,489,572 shares of CSTL stock, worth $28.8 Million. This represents 2.2% of its overall portfolio holdings.
Number of Shares
1,489,572
Previous 1,265,223
17.73%
Holding current value
$28.8 Million
Previous $25.3 Million
20.09%
% of portfolio
2.2%
Previous 2.07%
Shares
22 transactions
Others Institutions Holding CSTL
# of Institutions
168Shares Held
26.9MCall Options Held
0Put Options Held
0-
Black Rock Inc. New York, NY3.04MShares$58.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.17MShares$42 Million0.0% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.8MShares$34.8 Million0.02% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.38MShares$26.7 Million0.01% of portfolio
-
Nuveen, LLC Charlotte, NC1.07MShares$20.8 Million0.01% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $509M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...